Evidence map›Paper›PMID 37278097›Full record

ArticleInternational journal of cancer2023

Incidence of Burkitt lymphoma in the United States during 2000 to 2019.

Waruiru Mburu, Susan S Devesa, David Check, Meredith S Shiels, Sam M Mbulaiteye

Open access · greenAbstract read
In one paragraph

Article in International journal of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Waruiru MburuDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.
Susan S DevesaDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.
David CheckDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.
Meredith S ShielsDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.ORCID 0000-0001-8390-6091
Sam M MbulaiteyeDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.ORCID 0000-0002-8273-9831
National Cancer Institute · US

Funding

Epidemiology and Natural History of Cancer-Associated VirusesZIACP010176 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI MBULAITEYE, SAM M · 2009 to 2025
$33.7M
Intramural NIH HHS ZIA CP010176NCI NIH HHS HHSN261201100063C
6 · The paper itself

Abstract

Burkitt lymphoma (BL) is an aggressive B-cell lymphoma that occurs worldwide. A study of BL in the US National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) program during 1973 to 2005 (n = 3043) revealed three age-specific incidence peaks of BL and rates that were rising. We studied BL cases diagnosed in SEER 22 during 2000 to 2019 (n = 11 626) to investigate age-specific BL incidence rates and temporal trends. The age-standardized BL incidence rate was 3.96/million person-years, with a 2.85:1 male-to-female ratio. The BL rate among both Hispanic and White individuals was higher than in Black individuals (4.52, 4.12 vs 3.14). Age-specific BL rates showed peaks during pediatric, adult and elderly years in males and pediatric and elderly peaks in females. Based on 4524 BL cases with HIV status (SEER 13), only one peak in adult males (45 years) was observed. Overall age-standardized BL incidence rates rose 1.2%/year (not significant) up to 2009 then fell significantly by 2.4%/year thereafter. Temporal trends in BL rates during 2000 to 2019 varied with age group as pediatric BL rates rose 1.1%/year, while elderly BL rates fell 1.7%/year and adult BL rates rose 3.4%/year until 2007 before falling 3.1%/year thereafter. Overall survival from BL was 64% at 2 years, being highest in pediatric patients and lowest in Black and elderly individuals vs other subgroups. Survival improved by 20% between 2000 and 2019. Our data suggest that BL age-specific incidence rates are multimodal and that overall BL rates rose up to 2009 and then fell, suggesting changes in etiological factors or diagnosis.

Indexed as

Burkitt LymphomaNeoplasmsAdultAgedBlack or African AmericanBlack PeopleChildFemaleHispanic or LatinoHumansIncidenceMaleMiddle AgedUnited StatesWhiteBurkitt lymphomaepidemiologyEpstein-Barr virusHIVnon-Hodgkin lymphoma

Identifiers

PMID37278097
PMCPMC10524887
OpenAlexW4379508446

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.